Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that TrichoxidilTM positively affected hair growth by increasing growth factor expression and fibroblast proliferation, suggesting it may be a promising treatment for androgenetic alopecia.

This case report documents a 28-year-old woman who experienced complete scalp hair loss, which began a year earlier with patchy baldness and progressed to loss of eyebrow, axillary, and pubic hair.

This study identified several specific trichoscopic features of trichotillomania, with trichoptilosis, V hair, and hair powder being the most frequent findings.

This case report described acute vision loss in a patient after forehead injections of triamcinolone acetonide for alopecia areata, attributing retinal artery occlusion to embolization by steroid particles.

This study found that progesterone reduces neuronal injury from tributyltin exposure in rat hippocampal slices through a mechanism dependent on allopregnanolone and GABAA receptors.

This proof-of-concept study suggests that the new topical treatment regimen TH07 may offer effective hair growth results in men with androgenic alopecia, using a combination of finasteride, latanoprost, and minoxidil, supported by animal models and clinical studies.

This study found that TRH modulates specific keratins in human scalp tissue, suggesting its potential influence on hair growth and the need for further exploration of neuroendocrine controls in keratin expression.

The authors report a dementia patient who developed severe trichotillomania unresponsive to SSRIs, which improved with quetiapine; they suggest dopamine blockade may manage such symptoms in dementia.

This study successfully developed and characterized a monospecific monoclonal antibody, LHTric-1, that specifically localizes to the pre-cortical region of the hair follicle and can aid research on hair and nail formation.

This study found that intralesional triamcinolone acetonide was more effective than saline for hair regrowth in scalp alopecia areata, with 10 mg/mL showing the best response but more side effects.

This review discusses testosterone replacement therapy, highlighting that most studies report no increased myocardial infarction risk when the therapy is properly administered with controlled hormone levels; it calls for careful consideration despite insurance coverage challenges.

This study established an IRGDS model with diagnostic capability for alopecia areata, which may serve as an auxiliary marker for the condition.

In this case study, a 15-year-old girl with multiple trichoepitheliomas on her face saw a 90% reduction in lesions after combined cryotherapy and topical tretinoin treatment, with no scarring or recurrence over four years.

This review proposes a combination treatment scheme with a rotational approach for managing androgenetic alopecia, drawing on evidence for effectiveness, long-term use convenience, and patient acceptance, but presents no new clinical results.

CTP-543 is generally safe for treating alopecia areata.

This case report describes a woman with trichotillomania who experienced marked improvement and hair regrowth after off-label onabotulinumtoxinA treatment.

This study found that intralesional methotrexate and triamcinolone acetonide were significantly more effective than Vitamin D3 for hair regrowth in patients with alopecia areata.

This case report identifies an association between trichothiodystrophy and a urologic malformation with primary hypercalciuria, adding to the spectrum of TTD-related abnormalities.

This study found that the TrichoScan method detected significant increases in hair counts and cumulative hair thickness in men after finasteride treatment, suggesting its potential for monitoring hair treatment responses.

In this study, researchers examined trichoscopic features in 80 patients with androgenetic alopecia and found that hairshaft thickness heterogeneity was the most common feature, highlighting trichoscopy as a useful, non-invasive diagnostic tool for assessing this condition.

This study compared intralesional betamethasone and triamcinolone acetonide for treating alopecia areata and found that both were effective, with betamethasone 1.75mg/ml showing similar results to triamcinolone at 12 weeks without adverse effects.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

This study found that Atractylodes macrocephala Koidz. extract promotes anagen entry and hair regrowth by enhancing dermal papilla cell activity and supporting hair cycle progression in a mouse model.

This study developed a grooved microneedle platform enabling precise transdermal delivery of triamcinolone acetonide for alopecia areata, achieving accurate dosing by controlling groove position and drug concentration.

Trichohyalin in hair can trigger immune attacks in alopecia areata.

In this study, the authors evaluated 200 Egyptian children with focal non-cicatricial alopecia, finding that alopecia areata (42%) and tinea capitis (40.5%) were the most prevalent causes. Trichoscopy identified unique features for each condition, enhancing diagnosis and management.

In this study, Trapa bispinosa Roxb. pericarp extract demonstrated inhibitory effects on 5α-reductase activity both in vitro using LNCaP cells and in vivo in a mouse model of benign prostatic hyperplasia, suggesting its potential role in managing the condition.

This case report describes a rare autosomal dominant hair shaft disorder, monilethrix, observed in three consecutive generations of a family, with gradual improvement noted with age.